T

TMS Co Ltd
TSE:4891

Watchlist Manager
TMS Co Ltd
TSE:4891
Watchlist
Price: 212 JPY -3.2% Market Closed
Market Cap: 8.5B JPY
Have any thoughts about
TMS Co Ltd?
Write Note

TMS Co Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

TMS Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
T
TMS Co Ltd
TSE:4891
Revenue
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Revenue
ÂĄ22.7B
CAGR 3-Years
22%
CAGR 5-Years
27%
CAGR 10-Years
52%
PeptiDream Inc
TSE:4587
Revenue
ÂĄ47.8B
CAGR 3-Years
45%
CAGR 5-Years
47%
CAGR 10-Years
51%
Takara Bio Inc
TSE:4974
Revenue
ÂĄ44.1B
CAGR 3-Years
-10%
CAGR 5-Years
5%
CAGR 10-Years
6%
Pharma Foods International Co Ltd
TSE:2929
Revenue
ÂĄ60.6B
CAGR 3-Years
6%
CAGR 5-Years
41%
CAGR 10-Years
44%
C
Cuorips Inc
TSE:4894
Revenue
ÂĄ23.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

TMS Co Ltd
Glance View

Market Cap
8.5B JPY
Industry
Biotechnology

TMS Co., Ltd. engages in the research and development of pharmaceutical products and medical devices. The company is headquartered in Fuchu-Shi, Tokyo-To and currently employs 8 full-time employees. The company went IPO on 2022-11-22. The firm conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.

Intrinsic Value
103.44 JPY
Overvaluation 51%
Intrinsic Value
Price
T

See Also

What is TMS Co Ltd's Revenue?
Revenue
0 JPY

Based on the financial report for Feb 29, 2024, TMS Co Ltd's Revenue amounts to 0 JPY.

Back to Top